About D(1B) dopamine receptor
D(1B) dopamine receptor (DRD5) is a protein
from Homo sapiens identified by UniProt accession
P21918, 477 residues long.
MolForge cross-references it against 0 known binders and
214 disease associations.
Target properties
| Protein name | D(1B) dopamine receptor |
| UniProt accession | P21918 |
| Gene | DRD5 |
| Organism | Homo sapiens |
| Length | 477 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (214)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.53
- cardiovascular disease · score 0.53
- unipolar depression · score 0.50
- Parkinson disease · score 0.50
- Tourette syndrome · score 0.39
- psychosis · score 0.37
- Tics · score 0.37
- schizoaffective disorder · score 0.37
- Benign essential blepharospasm · score 0.37
- urate measurement · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P21918-F1 | alphafold | PREDICTED | 69.13 | — |
Amino-acid sequence (477 residues)
MLPPGSNGTA YPGQFALYQQ LAQGNAVGGS AGAPPLGPSQ VVTACLLTLL IIWTLLGNVL VCAAIVRSRH LRANMTNVFI VSLAVSDLFV ALLVMPWKAV AEVAGYWPFG AFCDVWVAFD IMCSTASILN LCVISVDRYW AISRPFRYKR KMTQRMALVM VGLAWTLSIL ISFIPVQLNW HRDQAASWGG LDLPNNLANW TPWEEDFWEP DVNAENCDSS LNRTYAISSS LISFYIPVAI MIVTYTRIYR IAQVQIRRIS SLERAAEHAQ SCRSSAACAP DTSLRASIKK ETKVLKTLSV IMGVFVCCWL PFFILNCMVP FCSGHPEGPP AGFPCVSETT FDVFVWFGWA NSSLNPVIYA FNADFQKVFA QLLGCSHFCS RTPVETVNIS NELISYNQDI VFHKEIAAAY IHMMPNAVTP GNREVDNDEE EGPFDRMFQI YQTSPDGDPV AESVWELDCE GEISLDKITP FTPNGFH
Explore D(1B) dopamine receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets